NVO vs. AZN
Compare and contrast key facts about Novo Nordisk A/S (NVO) and AstraZeneca PLC (AZN).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NVO or AZN.
Correlation
The correlation between NVO and AZN is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NVO vs. AZN - Performance Comparison
Key characteristics
NVO:
-1.19
AZN:
0.46
NVO:
-1.73
AZN:
0.73
NVO:
0.77
AZN:
1.10
NVO:
-0.87
AZN:
0.33
NVO:
-1.77
AZN:
0.67
NVO:
25.97%
AZN:
13.99%
NVO:
38.75%
AZN:
20.31%
NVO:
-71.29%
AZN:
-48.94%
NVO:
-52.77%
AZN:
-15.98%
Fundamentals
NVO:
$308.32B
AZN:
$225.70B
NVO:
$3.29
AZN:
$2.25
NVO:
20.68
AZN:
32.27
NVO:
1.05
AZN:
1.03
NVO:
$225.05B
AZN:
$41.39B
NVO:
$190.45B
AZN:
$33.41B
NVO:
$113.24B
AZN:
$12.65B
Returns By Period
In the year-to-date period, NVO achieves a -19.64% return, which is significantly lower than AZN's 12.36% return. Over the past 10 years, NVO has outperformed AZN with an annualized return of 11.83%, while AZN has yielded a comparatively lower 11.18% annualized return.
NVO
-19.64%
-23.74%
-41.42%
-45.60%
20.10%
11.83%
AZN
12.36%
-4.74%
-6.42%
10.14%
13.28%
11.18%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NVO vs. AZN — Risk-Adjusted Performance Rank
NVO
AZN
NVO vs. AZN - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NVO vs. AZN - Dividend Comparison
NVO's dividend yield for the trailing twelve months is around 2.37%, more than AZN's 2.11% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 2.37% | 1.68% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% |
AZN AstraZeneca PLC | 2.11% | 2.27% | 2.15% | 2.14% | 2.40% | 2.80% | 2.81% | 3.61% | 3.95% | 5.01% | 4.06% | 3.98% |
Drawdowns
NVO vs. AZN - Drawdown Comparison
The maximum NVO drawdown since its inception was -71.29%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for NVO and AZN. For additional features, visit the drawdowns tool.
Volatility
NVO vs. AZN - Volatility Comparison
Novo Nordisk A/S (NVO) has a higher volatility of 13.71% compared to AstraZeneca PLC (AZN) at 5.70%. This indicates that NVO's price experiences larger fluctuations and is considered to be riskier than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NVO vs. AZN - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities